CD274 and triple-negative breast carcinoma: For triple-negative breast cancer, PD-L1 positive expression has been reported in 41% of patients with metastatic disease enrolled in the Impassion 130 randomized trial (by using the SP142 Ventana assay, with a cut-off of ≥1% of total tumor area occupied by PD-L1+ immune cells) [54].